Sirio Pharma Co Ltd
SZSE:300791
Intrinsic Value
Sirio Pharma Co. Ltd. manufactures dietary supplement products. [ Read More ]
The intrinsic value of one
Sirio Pharma Co Ltd
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 39.84 CNY,
Sirio Pharma Co Ltd
is
hidden
.
Sirio Pharma Co Ltd's market capitalization is 7.2B CNY.
Sirio Pharma Co Ltd stock price is 39.84 CNY.
Sirio Pharma Co Ltd stock price (39.84 CNY) is 25% less than its Intrinsic Value (53.22 CNY).
Sirio Pharma Co Ltd stock (34.56 CNY) is 13% less than its price (39.84 CNY). Open DCF Valuation
Sirio Pharma Co Ltd stock price (39.84 CNY) is 45% less than its Relative Value (71.87 CNY). Open Relative Valuation
Sirio Pharma Co Ltd has upside potential of 2% compared to the average analyst price target.
Open Wall St Estimates
Sirio Pharma Co Ltd has positive three-year average ROE (Return on Equity): 10%. The company is efficient at transforming stockholders' equity into net income.
Sirio Pharma Co Ltd has positive three-year average ROIC (Return on Invested Capital): 10%. The company is efficient at using invested capital to generate operating income.
Sirio Pharma Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 12% to 12%.
Sirio Pharma Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 10%.
Sirio Pharma Co Ltd has positive Operating Income for the last twelve months.
Sirio Pharma Co Ltd has positive Net Debt. This means that the company has more debt (1B CNY) than cash and short-term investments (743m CNY).
Sirio Pharma Co Ltd has positive Net Income for the last twelve months.
Sirio Pharma Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 12%.
Sirio Pharma Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 14% to 10%.
Sirio Pharma Co Ltd has negative Free Cash Flow for the last twelve months.
Sirio Pharma Co Ltd's Revenue has grown by an exceptional 37% over the past 12 months.
Sirio Pharma Co Ltd's Revenue is forecast to grow at a rate of 17% per year over the next 3 years.
Sirio Pharma Co Ltd's Altman Z-Score is equal to 2.92.
Sirio Pharma Co Ltd's Revenue has been growing by an exceptional 20% per year for the last 3 years.
Sirio Pharma Co Ltd has positive Gross Profit for the last twelve months.
Sirio Pharma Co Ltd's long-term assets (5B CNY) exceed its long-term liabilties (3B CNY).
Sirio Pharma Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.55.
Sirio Pharma Co Ltd's short-term assets (2B CNY) exceed its short-term liabilties (751m CNY).
Valuation Backtest
Sirio Pharma Co Ltd
Run backtest to discover the historical profit from buying and selling
Sirio Pharma Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Sirio Pharma Co Ltd
Balance Sheet Decomposition
Sirio Pharma Co Ltd
| Current Assets | 1.9B |
| Cash & Short-Term Investments | 742.6m |
| Receivables | 668.7m |
| Other Current Assets | 521.7m |
| Non-Current Assets | 3.3B |
| Long-Term Investments | 94.1m |
| PP&E | 2B |
| Intangibles | 998.3m |
| Other Non-Current Assets | 209.4m |
| Current Liabilities | 751.1m |
| Accounts Payable | 391.7m |
| Accrued Liabilities | 196.6m |
| Short-Term Debt | 6.4m |
| Other Current Liabilities | 156.4m |
| Non-Current Liabilities | 2.1B |
| Long-Term Debt | 1.3B |
| Other Non-Current Liabilities | 749.4m |
Earnings Waterfall
Sirio Pharma Co Ltd
|
Revenue
|
3.8B
CNY
|
|
Cost of Revenue
|
-2.7B
CNY
|
|
Gross Profit
|
1.2B
CNY
|
|
Operating Expenses
|
-711m
CNY
|
|
Operating Income
|
445.4m
CNY
|
|
Other Expenses
|
-130.7m
CNY
|
|
Net Income
|
314.7m
CNY
|
Free Cash Flow Analysis
Sirio Pharma Co Ltd
Profitability Score
Profitability Due Diligence
Sirio Pharma Co Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Sirio Pharma Co Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Sirio Pharma Co Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Sirio Pharma Co Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Sirio Pharma Co Ltd
According to Wall Street analysts, the average 1-year price target for
Sirio Pharma Co Ltd
is 40.55 CNY
with a low forecast of 39.9 CNY and a high forecast of 42 CNY.
Shareholder Return
Price
Sirio Pharma Co Ltd
| Average Annual Return | 14.95% |
| Standard Deviation of Annual Returns | 75.41% |
| Max Drawdown | -73% |
| Market Capitalization | 7.2B CNY |
| Shares Outstanding | 181 562 337 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Sirio Pharma Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Sirio Pharma Co. Ltd. manufactures dietary supplement products. The company is headquartered in Shantou, Guangdong and currently employs 2,456 full-time employees. The company went IPO on 2019-09-25. The firm's main products include soft capsules, tablets, powders, soft candy, hard capsules and oral liquids. The firm's own brand is WEWOW nutritional health food. The firm distributes its products both in the domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Sirio Pharma Co Ltd
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 39.84 CNY,
Sirio Pharma Co Ltd
is
hidden
.
You don't have any saved screeners yet
